Two-photon imaging allows tracking the formation of Tau aggregates in the same brain-region of a live animal over the course of time. This makes it possible to study the effects of treatment longitudinally in vivo.
Longitudinal imaging of Tau aggregates in vivo by two-photon imaging available in reMYND’s Tau.P301S model
Transgenic mouse model of combined Abeta and tau pathology
The interplay of Abeta and Tau is considered detrimental if not crucial for disease etiology and progression of Alzheimer’s Disease.
Robust LTP measurements in Tau models
Long term potentiation (LTP), a reflection of dendritic spine density and synaptic plasticity, is gaining importance as a functional ex-vivo or even in-vivo read-out related to learning and memory.
LTP measurements available through reMYND
reMYND now offers Long Term Potentiation (LTP) measurements to allow clients to assess the effect of their experimental Alzheimer treatment.
reMYND’s novel diabetes treatment prevents – and even reverses – disease progression in pre-clinical diabetes models
Press release | reMYND NV announced today that its experimental diabetes drug ReS39 has demonstrated a strong disease modifying effect in mice, in which the insulin producing capacity of β-cells is preserved - possibly even restored– in a durable way through a novel mechanism of action.